Progenics Pharmaceuticals Inc

Most Recent

  • uploads///Opko Health analysts
    Earnings Report

    Opko Health: Q2 Expenditures, Developments, Recommendations

    Opko Health’s (OPK) cost of revenues declined from $157.4 million in Q2 2017 to $150.1 million in Q2 2018.

    By Daniel Collins
  • uploads///capsule _
    Company & Industry Overviews

    How Analysts View Amicus Therapeutics in September

    Amicus Therapeutics (FOLD) plans to start the pivotal trial for AT-GAA in the second half of 2018.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday

    On Tuesday, September 25, Acadia Pharmaceuticals (ACAD) stock closed at $21.41. That’s 7.86% higher than its prior day’s close of $19.85.

    By Daniel Collins
  • uploads///Invitae
    Company & Industry Overviews

    Why Invitae Stock Rose 23% in Week Ended August 24

    On August 24, Invitae (NVTA) stock closed at $12.56, which represents a ~4.75% growth from its prior day’s close of $11.99.

    By Daniel Collins
  • uploads///NKTR
    Company & Industry Overviews

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).

    By Kenneth Smith
  • uploads///Opko Health
    Earnings Report

    How Opko Health Fared in the Second Quarter of 2018

    Opko Health (OPK) generated net revenues of $263.7 million in the second quarter of 2018 compared to $292.6 million in Q2 of 2017.

    By Daniel Collins
  • uploads///analysis _
    Company & Industry Overviews

    What Analysts Think of PolarityTE and Its Peers

    In June, PolarityTE stock has been given a “buy” rating by the one analyst covering it. The target price for the stock is $65.

    By Kenneth Smith
  • uploads///capsule _
    Company & Industry Overviews

    What’s the Upside Potential of Nektar Therapeutics?

    Of the 12 analysts covering Nektar Therapeutics in June 2018, 11 analysts have given the stock a “buy” or higher rating.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.